AHDB

Current Issue

The Medical and Economic Burden of Narcolepsy: Implications for Managed Care

Michael J. Thorpy, MB, ChB, George Hiller, RPh

July 2017 Vol 10, No 5 - Clinical

Stakeholder Perspective

Improved Diagnosis and Treatment of Narcolepsy May Also Help to Reduce the Associated Costs

by James T. Kenney, RPh, MBA

Emphasize Shared Decision-Making Between Physicians and Patients to Improve Diabetes Outcomes

Gary Branning, MBA, Stacey L. Worthy, Esq, Martha Vater

July 2017 Vol 10, No 5 - Industry Trends

Value Frameworks in Oncology: Comparative Analysis and Implications to the Pharmaceutical Industry

Mark Slomiany, PhD, MBA, MPA, Priya Madhavan, Michael Kuehn, Sasha Richardson, MBA

July 2017 Vol 10, No 5 - Business

Stakeholder Perspective

Payers’ Utilization of Value Frameworks Tools in Their Drug Coverage Decision-Making

by Matthew Mitchell, PharmD, MBA, FAMCP

Budget Impact of a Comprehensive Nutrition-Focused Quality Improvement Program for Malnourished Hospitalized Patients

Suela Sulo, PhD, Josh Feldstein, BA, Jamie Partridge, PhD, MBA, Bjoern Schwander, MS, RN, Krishnan Sriram, MD, Wm. Thomas Summerfelt, PhD

July 2017 Vol 10, No 5 - Business, Original Research

Stakeholder Perspective

The Crucial Role of Nutrition Support Services for Hospitalized Patients

by Jack E. Fincham, PhD, RPh

Conference Correspondent

Clinical Outcomes of Patients with DLBCL, FL, and Richter Transformation Treated with Ibrutinib: A Real-World Experience of Off-Label Ibrutinib Use

Conference Correspondent - ASCO 2017 - Chronic Lymphocytic Leukemia, Conference Correspondent

A Genetic Risk-Stratified Phase 2 Study of Fludarabine/Antibody Combinations in Symptomatic, Untreated CLL: Results from Cancer and Leukemia Group B (CALGB) 10404 (Alliance)

Conference Correspondent - ASCO 2017 - Chronic Lymphocytic Leukemia, Conference Correspondent

Ublituximab and Ibrutinib for Previously Treated, Genetically High-Risk CLL: Results of the GENUINE Phase 3 Study

Conference Correspondent - ASCO 2017 - Chronic Lymphocytic Leukemia, Conference Correspondent

Long-Term Efficacy and Safety with Ibrutinib in Previously Treated CLL: Up to 4 Years’ Follow-Up of the RESONATE Study

Conference Correspondent - ASCO 2017 - Chronic Lymphocytic Leukemia, Conference Correspondent

Most Popular Articles

Long-Term Efficacy and Safety with Ibrutinib in Previously Treated CLL: Up to 4 Years’ Follow-Up of the RESONATE Study

Conference Correspondent - ASCO 2017 - Chronic Lymphocytic Leukemia, Conference Correspondent

Ublituximab and Ibrutinib for Previously Treated, Genetically High-Risk CLL: Results of the GENUINE Phase 3 Study

Conference Correspondent - ASCO 2017 - Chronic Lymphocytic Leukemia, Conference Correspondent

Clinical Outcomes of Patients with DLBCL, FL, and Richter Transformation Treated with Ibrutinib: A Real-World Experience of Off-Label Ibrutinib Use

Conference Correspondent - ASCO 2017 - Chronic Lymphocytic Leukemia, Conference Correspondent

A Genetic Risk-Stratified Phase 2 Study of Fludarabine/Antibody Combinations in Symptomatic, Untreated CLL: Results from Cancer and Leukemia Group B (CALGB) 10404 (Alliance)

Conference Correspondent - ASCO 2017 - Chronic Lymphocytic Leukemia, Conference Correspondent

Comparing Medication Adherence and Persistence Among Patients with Type 2 Diabetes Using Sodium-Glucose Cotransporter 2 Inhibitors or Sulfonylureas

Kelly F. Bell, PharmD, MSPhr, MS, Katherine Cappell, PhD, Michael Liang, MS, Amanda M. Kong, MPH

June 2017 Vol 10, No 4 - Clinical, Original Research

Web Exclusives

Neratinib First Extended Adjuvant Treatment for Patients with Early-Stage, HER2-Positive Breast Cancer

HER2-positive breast cancers are aggressive tumors and can spread to other parts of the body, making adjuvant therapy an important part of the treatment plan.